TBnet webinar
Today, 28 November at 17:00 CET the TBnet webinar
TB biomarkers: host vs. pathogen
More information and free registration: https://www.tbnet.eu/post/tbnet-webinar-tb-biomarkers-host-vs-pathogen-on-28-november
UNITE4TB webinar
Also today, 28 November at 13:00 CET the UNITE4TB webinar with our former Steering Committee member Dr Jessica Porter
Panel discussion on intersecting vulnerabilities of TB in migrants: prevention and care strategies
More information and free registration: https://www.ersnet.org/events/panel-discussion-on-intersecting-vulnerabilities-of-tb-in-migrants-prevention-and-care-strategies/
We hope to see you at both webinars today!
Learn more about NTMnet
NTMnet is involved in several important projects aimed at improving the management and treatment of nontuberculous mycobacterial (NTM) disease. These include a survey to understand variations in clinical practice for managing NTM pulmonary disease (NTM-PD) across Europe, providing insights to better support healthcare providers. An NTMnet-endorsed prospective study is also ongoing to evaluate real-life treatment outcomes of guideline-based therapy for Mycobacterium avium complex (MAC) disease (NCT05906316). Another initiative focuses on assessing the effectiveness of a patient diary as a simple tool to monitor treatment responses and detect potential failures in NTM-PD patients. Additionally, a global survey explores the use of therapeutic drug monitoring in NTM treatment and identifies barriers to its implementation.
For more information on these projects and contact details, visit the NTMnet website: www.ntmnet.org/projects
Survey on the use of therapeutic drug monitoring for treatment of nontuberculous mycobacterial infections - a NTMnet/ESGMYC collaborative study
- a survey by Victor Næstholt Dahl, Nicole Maranchick, Rob Aarnoutse, and Jakko van Ingen The treatment of infections with nontuberculous mycobacteria (NTM) is long and involves multiple drugs often associated with adverse effects. Microbiological recurrence after treatment is common. Information on the use of therapeutic drug monitoring (TDM) to optimize the treatment of NTM disease is very sparse, and only a few studies have provided data on its clinical implications. With this survey, we aim to describe the use of TDM in the treatment of NTM disease and barriers to implementation globally. We invite you to share your valuable insights on NTM disease management by participating in our survey. Your feedback is crucial in helping us improve the understanding of the use of TDM in NTM disease treatment. The survey will take approximately 5-10 minutes, and your responses remain confidential. All questions relate to the use of TDM in patients with NTM disease and not in patients with tuberculosis. We would very much like your participation if you work with NTM patients in clinical practice or are involved in NTM disease and TDM in other ways (e.g., laboratory work or research).
The survey is kindly distributed by NTMnet and ESGMYC, but we would appreciate it if you shared it with other relevant individuals or societies within your country or network.
Inquiries about the survey can be addressed to Dr. Victor Næstholt Dahl at victor.dahl@rm.dk
Thank you for your time and contribution!
Access the survey:
Click here
Use the link https://redcap.rm.dk/surveys/?s=33M3CTJ7RPEK3XX7
Scan the QR code (below)
TBnet News
Editor – Irina Kontsevaya
Layout & formatting – Liga Rusmane
Cover picture – Irina Kontsevaya
Comments